Latest results from PHOEBE trial show patients with advanced HER2-positive breast cancer live longer on pyrotinib
This item is under embargo and is only visible to journalists
Please login here
Regions: Europe, Portugal, Asia, China
Keywords: Health, Medical
Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
The item has been withdrawn. If you are a journalists please contact the person that posted the item with any questions.